Table 3. Estimated detection rates for daily snapshot monitoring classified based on low/high CHADS2 score and low/high AT/AF burden (n = 370).
| Monitoring window of simulated daily snapshots | Number of patients with CIED data in window | Number of AT/AF patients detected by CIED in window (%) | Number of AT/AF patients detected by snapshot monitoring | |
|---|---|---|---|---|
| % of total patients | % of patients with AT/AF in window | |||
| CHADS2 score | ||||
| Intermediate risk group (n = 91) | ||||
| 14 days | 91 | 25 (27.5 [18.6–37.8]%) | 11/91 (12.1 [6.2–20.6]%) | 11/25 (44.0 [24.4–65.1]%) |
| 28 days | 91 | 37 (40.7 [30.5–51.5]%) | 16/91 (17.6 [10.4–27.0]%) | 16/37 (43.2 [27.1–60.5]%) |
| 56 days | 89 | 41 (46.1 [35.4–57.0]%) | 20/89 (22.5 [14.3–32.6]%) | 20/41 (48.8 [32.9–64.9]%) |
| 112 days | 88 | 59 (67.0 [56.2–76.7]%) | 25/88 (28.4 [19.3–39.0]%) | 25/59 (42.4 [29.6–55.9]%) |
| 365 days | 61 | 61 (100.0%) | 23/61 (37.7 [25.6–51.0]%) | 23/61 (37.7 [25.6–51.0]%) |
| High risk group (n = 279) | ||||
| 14 days | 279 | 67 (24.0 [19.1–29.5]%) | 26/279 (9.3 [6.2–13.4]%) | 26/67 (38.8 [27.1–51.5]%) |
| 28 days | 275 | 85 (30.9 [25.5–36.7]%) | 38/275 (13.8 [10.0–18.5]%) | 38/85 (44.7 [33.9–55.9]%) |
| 56 days | 270 | 125 (46.3 [40.2–52.4]%) | 57/270 (21.1 [16.4–26.5]%) | 57/125 (45.6 [36.7–54.7]%) |
| 112 days | 263 | 170 (64.6 [58.5–70.4]%) | 74/263 (28.1 [22.8–34.0]%) | 74/170 (43.5 [36.0–51.3]%) |
| 365 days | 193 | 193 (100.0%) | 103/193 (53.4 [46.1–60.6]%) | 103/193 (53.4 [46.1–60.6]%) |
| AT/AF burden | ||||
| Low burden Group (n = 185) | ||||
| 14 days | 185 | 22 (11.9 [7.6–17.4]%) | 1/185 (0.5 [0.0–3.0]%) | 1/22 (4.5 [0.1–22.8]%) |
| 28 days | 184 | 34 (18.5 [13.1–24.9]%) | 2/184 (1.1 [0.1–3.9]%) | 2/34 (5.9 [0.7–19.7]%) |
| 56 days | 183 | 57 (31.1 [24.5–38.4]%) | 6/183 (3.3 [1.2–7.0]%) | 6/57 (10.5 [4.0–21.5]%) |
| 112 days | 181 | 103 (56.9 [49.4–64.2]%) | 10/181 (5.5 [2.7–9.9]%) | 10/103 (9.7 [4.8–17.1]%) |
| 365 days | 135 | 135 (100.0%) | 19/135 (14.1 [8.7–21.1]%) | 19/135 (14.1 [8.7–21.1]%) |
| High burden Group (n = 185) | ||||
| 14 days | 185 | 70 (37.8 [30.8–45.2]%) | 36/185 (19.5 [14.0–25.9]%) | 36/70 (51.4 [39.2–63.6]%) |
| 28 days | 182 | 88 (48.4 [40.9–55.9]%) | 52/182 (28.6 [22.1–35.7]%) | 52/88 (59.1 [48.1–69.5]%) |
| 56 days | 176 | 109 (61.9 [54.3–69.1]%) | 71/176 (40.3 [33.0–48.0]%) | 71/109 (65.1 [55.4–74.0]%) |
| 112 days | 170 | 126 (74.1 [66.9–80.5]%) | 89/170 (52.4 [44.6–60.1]%) | 89/126 (70.6 [61.9–78.4]%) |
| 365 days | 119 | 119 (100.0%) | 108/119 (90.8 [84.1–95.3]%) | 108/119 (90.8 [84.1–95.3]%) |
370 patients were divided into risk groups based on CHADS2 score (intermediate risk [a CHADS2 score of 1] or high risk [a CHADS2 score of ≥2]) and AF burden (low AT/AF burden [less than the median average daily AT/AF burden of 0.044 hours/day] or high AT/AF burden [greater than or equal to the median average daily AT/AF burden of 0.044 hours/day]). Data are expressed as means [95% confidence intervals] of estimated AT/AF detection rates with the snapshot monitoring. CIED indicates cardiac implantable electronic device; AT, atrial tachycardia; AF, atrial fibrillation.